MYH9 explained
Myosin-9 also known as myosin, heavy chain 9, non-muscle or non-muscle myosin heavy chain IIa (NMMHC-IIA) is a protein which in humans is encoded by the MYH9 gene.[1] [2]
Non-muscle myosin IIA (NM IIA) is expressed in most cells and tissues where it participates in a variety of processes requiring contractile force, such as cytokinesis, cell migration, polarization and adhesion, maintenance of cell shape, and signal transduction. Myosin IIs are motor proteins that are part of a superfamily composed of more than 30 classes.[3] [4] [5] Class II myosins include muscle and non-muscle myosins that are organized as hexameric molecules consisting of two heavy chains (230 kDa), two regulatory light chains (20 KDa) controlling the myosin activity, and two essential light chains (17 kDa), which stabilize the heavy chain structure.[6] [7] [8] [9] [10]
Gene
MYH9 is a large gene spanning more than 106 kilo base pairs on chromosome 22q12.3. It is composed of 41 exons with the first ATG of the open reading frame localized in exon 2 and the stop codon in exon 41. It encodes non-muscle myosin heavy chain IIA (NMHC IIA), a protein of 1,960 amino acids. Consistent with its wide expression in cells and tissues, the promoter region of MYH9 is typical of housekeeping genes having no TATA box but high GC content, with multiple GC boxes. MYH9 is a well-conserved gene through evolution. The mouse ortholog (Myh9) is localized in a syntenic region on chromosome 15 and has the same genomic organization as that of the human gene. It encodes a protein of the same length, with 97.1% amino acid identity with the human MYH9 protein.[11]
Tissue distribution
There are significant differences in the relative abundance of the three NM II paralogs in various cells and tissues. However, NM IIA appears to be the predominant paralog in both tissues and cells in humans and mice. Mass spectroscopy analysis of the relative abundance of NMHC IIs in mouse tissues and human cell lines[12] shows that NM IIA is predominant, although tissues like the heart vary from cell to cell; myocardial cells contain only NM IIB but NM IIA is more abundant in the non-myocyte cells. NM IIB is predominant in most parts of the brain and spinal cord but NM IIA is relatively more abundant in most other organs and cells lines. Both NM IIA and IIB are expressed early in development with NM IIC expression starting at E 11.5 in mice. Not only do most cells contain more than one paralog but there is evidence that the paralogs can co-assemble intracellularly into heterotypic filaments in a variety of settings in cultured cells.[13] [14] [15]
Structure
Like all class II myosins, the two NMHC IIAs dimerize producing an asymmetric molecular structure recognizable by two heads and a tail domain: the N-terminal half of each heavy chain generates the head domain, which consists of the globular motor domain and the neck domain, and the C-terminal halves of the two heavy chains together form the tail domain.[16] The motor domain, which is organized into four subdomains (SH3-like motif, the upper and the lower 50kDa subdomains, and the converter region) connected by flexible linkers,[17] interacts with filamentous actin to generate force through magnesium-dependent hydrolysis of ATP. The neck acts as a lever arm that amplifies the movement produced by conformational changes of the motor domain, and is the binding site for the light chains through two IQ motifs. The tail domain is fundamental for both dimerization of the heavy chains and formation of NM IIA functional filaments. Two heavy chains dimerize through the tail domain forming a long alpha-helical coiled-coil rod composed of typical heptad repeats. Dimers self-associate though the coiled-coil rods to form myosin filaments. The tail domain ends at the C-terminus with a 34-residue non-helical tailpiece.
Function
NM IIA plays a major role in early vertebrate development. Ablation of NM IIA in mice results in lethality by embryonic day (E) 6.5 due to abnormalities in the visceral endoderm which is disorganized due to a loss of E-cadherin mediated cell-cell adhesions.[18] Lacking a normal polarized columnar layer of endoderm, the abnormal visceral endoderm of NM IIA knockout embryos fails to support the critical step of gastrulation. However, the development of a normal functioning visceral endoderm does not specifically depend on NM IIA since its function can be restored by genetically replacing the NMHC IIA with cDNA encoding NMHC II B (or NMHC IIC) that is under control of the NMHC IIA promoter.[19] These "replacement" mice have a normal visceral endoderm and continue to proceed through gastrulation and undergo organogenesis. However, they die when they fail to develop a normal placenta. Absence of NM IIA results in a compact and underdeveloped labyrinthine layer in the placenta which lacks fetal blood vessel invasion. Moreover, mutant p.R702C NM IIA mice show similar defects in placental formation[20] and mice specifically ablated for NM IIA in the mouse trophoblast-lineage cells demonstrate placental defects similar to mice in which NMHC IIA is genetically replaced by NMHC IIB.[21]
Regulation
There are three paralogs of non-muscle myosin II (NM II), NM IIA, IIB, and IIC, with each having the heavy chain encoded on a different chromosome. All three paralogs appear to bind the same or very similar light chains and share basic properties as to structure and activation, but all three play distinct roles during vertebrate development and adulthood (for general reviews on NM IIs, see). All NM IIs have two important features: they are MgATPase enzymes that can hydrolyze ATP thereby converting chemical energy into mechanical movement. In addition, they can form bipolar filaments which can interact with and exert tension on actin filaments. These properties provide the basis for all NM II functions. The path to myosin filament formation, which is shared by NM II and smooth muscle myosin, starts with a folded inactive conformation of the NM II monomer which, upon phosphorylation of the 20 KDa light chain unfolds the molecule to produce a globular head region followed by an extended alpha-helical coiled-coil tail.[22] [23] [24] [25] The tail portion of the molecule can interact with other NM IIA hexamers to form bipolar filaments composed of 14-16 molecules.
Phosphorylation of the 20 KDa light chains on Serine 19 and Threonine 18 by a number of different kinases, but most prominently by Rho-dependent kinase and/or by the calcium-calmodulin-dependent myosin light chain kinase, not only linearizes the folded structure but removes the inhibition imposed on the MgATPase activity due to the folded conformation. In addition to phosphorylation of the 20 KDa light chains, the NMHC IIs can also be phosphorylated, but the sites phosphorylated differ among the paralogs. In most cases phosphorylation of NMHC IIA can act to either dissociate the myosin filaments or to prevent filament formation.
In addition to phosphorylation, NM IIA filament assembly and localization can be modulated by interaction with other proteins including S100A4 and Lethal giant larvae (Lgl1). The former is a calcium binding protein and is also known as metastatin, a well-characterized metastatic factor. S100A4 expression is associated with enhanced cell migration through maintenance of cell polarization and inhibition of cell turning.[26] [27] Similar to heavy chain phosphorylation, in vitro binding of S100A to the carboxy-terminal end of the NM IIA coiled-coil region prevents filament formation and S100A4 binding to previously formed filaments promotes filament disassembly. The tumor suppressor protein Lgl1 also inhibits the ability of NM IIA to assemble into filaments in vitro.[28] [29] In addition, it regulates the cellular localization of NM IIA and contributes to the maturation of focal adhesions. Other proteins that are known to interact with NM IIA include the actin binding protein tropomyosin 4.2 [30] and a novel actin stress fiber associated protein, LIM and calponin-homology domains1 (LIMCH1).[31]
Clinical significance
MYH9-RD
Mutations in MYH9 cause a Mendelian autosomal dominant disorder known as MYH9-related disease (MYH9-RD).[32] [33] [34] [35] The disease encompasses four syndromic variants that were historically considered distinct—May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome—but are now recognized as variable clinical presentations of the same condition.MYH9-RD is a rare disorder with an estimated prevalence of 3 per 1,000,000. However, actual prevalence is likely higher due to underdiagnosis of mild or asymptomatic cases. The disease has been reported globally, with no apparent ethnic variation.[36]
Clinical features
All patients present with congenital thrombocytopenia and giant platelets. Blood smears consistently show platelets larger than red blood cells.[37] Granulocytes contain cytoplasmic inclusions of the MYH9 protein (NMHC IIA), appearing as Döhle-like bodies on conventional staining.Bleeding tendency is variable. Most individuals have no spontaneous bleeding or only mild symptoms (e.g., bruising). Severe hemorrhage is uncommon and usually provoked by trauma, surgery, or childbirth. Some patients experience mucosal bleeding, such as menorrhagia, epistaxis, or gingival bleeding.[38]
More than 50% of patients develop sensorineural hearing loss. Severity is highly variable, ranging from mild, late-onset impairment to early-onset progressive deafness.[39] Renal involvement affects about 25% of patients and typically begins with proteinuria, sometimes progressing to renal failure requiring dialysis or transplantation. Approximately 20% develop presenile cataracts. Around 50% of patients have chronic or intermittent elevation of liver enzymes; this is generally benign and not associated with liver dysfunction.[40]
Diagnosis
Diagnosis is confirmed by detecting cytoplasmic NMHC IIA inclusions in granulocytes via immunofluorescence on blood smears,[41] [42] or by identifying pathogenic variants in the MYH9 gene via molecular testing.[43] [44]
Genetics
MYH9-RD is typically caused by missense mutations affecting the head or tail domains of NMHC IIA. About 20% of cases involve nonsense or frameshift mutations that delete 17–40 residues at the C-terminus. In-frame deletions or duplications are rare.[45] The disorder follows an autosomal dominant inheritance pattern. Nevertheless, approximately 35% of index cases are sporadic due to de novo mutations. Rarely, germline or somatic mosaicism is identified.[46] [47] [48]
The severity and onset of non-congenital manifestations correlate with the specific MYH9 mutation. Genotype–phenotype relationships also extend to platelet count, platelet size, and inclusion characteristics.[49] [50]
Management
Treatment is primarily supportive. In a phase 2 trial, the thrombopoietin receptor agonist eltrombopag significantly increased platelet counts in 11 of 12 patients.[51] Early use of ACE inhibitors or angiotensin receptor blockers may slow progression of renal disease by reducing proteinuria.[52] [53] For patients with severe or profound deafness, cochlear implantation has been shown to be safe and effective.[54]
Cancer
Evidence obtained in animals indicates that MYH9 acts as a tumor suppressor gene. Silencing of Myh9 in the epithelial cells in mice was associated with the development of squamous cell carcinoma (SCC) of the skin and the head and neck.[55] In another mouse model, ablation of Myh9 in the tongue epithelium led to the development of tongue SCC.[56] In mice predisposed to invasive lobular breast carcinoma (ILBC) because of E-cadherin ablation, the inactivation of Myh9 led to the development of tumors recapitulating the features of human ILBC.[57] Some observations suggest that defective MYH9 expression is associated with oncogenesis and/or tumor progression in human SCC and ILBC, thus also supporting a role for MYH9 as a tumor suppressor in humans.
Chronic kidney disease
Genetic variations in MYH9 may be involved in predisposition to chronic kidney disease (CKD). A haplotype of MYH9 (haplotype E1) was previously associated with the increased prevalence of glomerulosclerosis[58] and non-diabetic end stage renal disease[59] in African Americans and in Hispanic Americans.[60] However, subsequent studies showed that this association is explained by strong linkage disequilibrium with two haplotypes (haplotypes G1 and G2) in the neighboring APOL1 gene.[61] [62] [63] Nevertheless, some studies suggest an association of single-nucleotide polymorphisms in MYH9 with CKD that appears to be independent of the linkage with APOL1 G1 and G2.[64] [65] [66]
Hearing loss
Inherited MYH9 mutations may be responsible for non-syndromic hearing loss.[67] [68] [69]
Interactions
MYH9 has been shown to interact with PRKCE.[70]
See also
Further reading
- Starr R, Offer G . The interaction of C-protein with heavy meromyosin and subfragment-2 . The Biochemical Journal . 171 . 3 . 813–6 . June 1978 . 352343 . 1184031 . 10.1042/bj1710813.
- Lee CL, Atassi MZ . Enzymic and immunochemical properties of lysozyme. Accurate definition of the antigenic site around the disulphide bridge 30-115 (site 3) by 'surface-simulation' synthesis . The Biochemical Journal . 167 . 3 . 571–81 . December 1977 . 603622 . 1183703 . 10.1042/bj1670571.
- Tweed WA, Phua WT, Chong KY, Lim E, Lee TL . Large tidal volume ventilation improves pulmonary gas exchange during lower abdominal surgery in Trendelenburg's position . Canadian Journal of Anaesthesia . 38 . 8 . 989–95 . November 1991 . 1752022 . 10.1007/BF03008617 . free .
- Simons M, Wang M, McBride OW, Kawamoto S, Yamakawa K, Gdula D, Adelstein RS, Weir L . Human nonmuscle myosin heavy chains are encoded by two genes located on different chromosomes . Circulation Research . 69 . 2 . 530–9 . August 1991 . 1860190 . 10.1161/01.res.69.2.530 . free .
- Toothaker LE, Gonzalez DA, Tung N, Lemons RS, Le Beau MM, Arnaout MA, Clayton LK, Tenen DG . Cellular myosin heavy chain in human leukocytes: isolation of 5' cDNA clones, characterization of the protein, chromosomal localization, and upregulation during myeloid differentiation . Blood . 78 . 7 . 1826–33 . October 1991 . 1912569 . 10.1182/blood.V78.7.1826.1826. free .
- Saez CG, Myers JC, Shows TB, Leinwand LA . Human nonmuscle myosin heavy chain mRNA: generation of diversity through alternative polyadenylylation . Proceedings of the National Academy of Sciences of the United States of America . 87 . 3 . 1164–8 . February 1990 . 1967836 . 53431 . 10.1073/pnas.87.3.1164 . 1990PNAS...87.1164S . free .
- Moos C, Feng IN . Effect of C-protein on actomyosin ATPase . Biochimica et Biophysica Acta (BBA) - General Subjects . 632 . 2 . 141–9 . October 1980 . 6448079 . 10.1016/0304-4165(80)90071-9 .
- Obermann WM, Plessmann U, Weber K, Fürst DO . Purification and biochemical characterization of myomesin, a myosin-binding and titin-binding protein, from bovine skeletal muscle . European Journal of Biochemistry . 233 . 1 . 110–5 . October 1995 . 7588733 . 10.1111/j.1432-1033.1995.110_1.x .
- Maupin P, Phillips CL, Adelstein RS, Pollard TD . Differential localization of myosin-II isozymes in human cultured cells and blood cells . Journal of Cell Science . 107 . 11 . 3077–90 . November 1994 . 10.1242/jcs.107.11.3077 . 7699007 .
- Bement WM, Hasson T, Wirth JA, Cheney RE, Mooseker MS . Identification and overlapping expression of multiple unconventional myosin genes in vertebrate cell types . Proceedings of the National Academy of Sciences of the United States of America . 91 . 14 . 6549–53 . July 1994 . 8022818 . 44240 . 10.1073/pnas.91.14.6549 . 1994PNAS...91.6549B . free .
- Eilertsen KJ, Kazmierski ST, Keller TC . Cellular titin localization in stress fibers and interaction with myosin II filaments in vitro . The Journal of Cell Biology . 126 . 5 . 1201–10 . September 1994 . 8063857 . 2120159 . 10.1083/jcb.126.5.1201 .
- Shoeman RL, Sachse C, Höner B, Mothes E, Kaufmann M, Traub P . Cleavage of human and mouse cytoskeletal and sarcomeric proteins by human immunodeficiency virus type 1 protease. Actin, desmin, myosin, and tropomyosin . The American Journal of Pathology . 142 . 1 . 221–30 . January 1993 . 8424456 . 1886840 .
- Lalwani AK, Linthicum FH, Wilcox ER, Moore JK, Walters FC, San Agustin TB, Mislinski J, Miller MR, Sinninger Y, Attaie A, Luxford WM . A five-generation family with late-onset progressive hereditary hearing impairment due to cochleosaccular degeneration . Audiology and Neuro-Otology . 2 . 3 . 139–54 . 1998 . 9390828 . 10.1159/000259237 .
- Ford HL, Silver DL, Kachar B, Sellers JR, Zain SB . Effect of Mts1 on the structure and activity of nonmuscle myosin II . Biochemistry . 36 . 51 . 16321–7 . December 1997 . 9405067 . 10.1021/bi971182l .
- Obermann WM, van der Ven PF, Steiner F, Weber K, Fürst DO . Mapping of a myosin-binding domain and a regulatory phosphorylation site in M-protein, a structural protein of the sarcomeric M band . Molecular Biology of the Cell . 9 . 4 . 829–40 . April 1998 . 9529381 . 25310 . 10.1091/mbc.9.4.829 .
- Dunham I, Shimizu N, Roe BA, Chissoe S, Hunt AR, Collins JE, Bruskiewich R, Beare DM, Clamp M, Smink LJ, Ainscough R, Almeida JP, Babbage A, Bagguley C, Bailey J, Barlow K, Bates KN, Beasley O, Bird CP, Blakey S, Bridgeman AM, Buck D, Burgess J, Burrill WD, O'Brien KP . The DNA sequence of human chromosome 22 . Nature . 402 . 6761 . 489–95 . December 1999 . 10591208 . 10.1038/990031 . 1999Natur.402..489D . free .
- Miyamoto CA, Fischman DA, Reinach FC . The interface between MyBP-C and myosin: site-directed mutagenesis of the CX myosin-binding domain of MyBP-C . Journal of Muscle Research and Cell Motility . 20 . 7 . 703–15 . October 1999 . 10672519 . 10.1023/A:1005513312939 . 20834690 .
- Sajid M, Hu Z, Lele M, Stouffer GA . Protein complexes involving alpha v beta 3 integrins, nonmuscle myosin heavy chain-A, and focal adhesion kinase from in thrombospondin-treated smooth muscle cells . Journal of Investigative Medicine . 48 . 3 . 190–7 . May 2000 . 10822899 .
- Husi H, Ward MA, Choudhary JS, Blackstock WP, Grant SG . Proteomic analysis of NMDA receptor-adhesion protein signaling complexes . Nature Neuroscience . 3 . 7 . 661–9 . July 2000 . 10862698 . 10.1038/76615 . 1842/742 . 14392630 . free .
- Kelley MJ, Jawien W, Lin A, Hoffmeister K, Pugh EW, Doheny KF, Korczak JF . Autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly) is linked to chromosome 22q12-13 . Human Genetics . 106 . 5 . 557–64 . May 2000 . 10914687 . 10.1007/s004390050025 .
External links
Notes and References
- Simons M, Wang M, McBride OW, Kawamoto S, Yamakawa K, Gdula D, Adelstein RS, Weir L . Human nonmuscle myosin heavy chains are encoded by two genes located on different chromosomes . Circulation Research . 69 . 2 . 530–9 . August 1991 . 1860190 . 10.1161/01.res.69.2.530 . free .
- Lalwani AK, Goldstein JA, Kelley MJ, Luxford W, Castelein CM, Mhatre AN . Human nonsyndromic hereditary deafness DFNA17 is due to a mutation in nonmuscle myosin MYH9 . American Journal of Human Genetics . 67 . 5 . 1121–8 . November 2000 . 11023810 . 1288554 . 10.1016/S0002-9297(07)62942-5 .
- Foth BJ, Goedecke MC, Soldati D . New insights into myosin evolution and classification . Proceedings of the National Academy of Sciences of the United States of America . 103 . 10 . 3681–6 . March 2006 . 16505385 . 1533776 . 10.1073/pnas.0506307103 . free .
- Odronitz F, Kollmar M . Drawing the tree of eukaryotic life based on the analysis of 2,269 manually annotated myosins from 328 species . Genome Biology . 8 . 9 . R196 . 2007 . 17877792 . 2375034 . 10.1186/gb-2007-8-9-r196 . free .
- Sebé-Pedrós A, Grau-Bové X, Richards TA, Ruiz-Trillo I . Evolution and classification of myosins, a paneukaryotic whole-genome approach . Genome Biology and Evolution . 6 . 2 . 290–305 . February 2014 . 24443438 . 3942036 . 10.1093/gbe/evu013 .
- Dulyaninova NG, Bresnick AR . The heavy chain has its day: regulation of myosin-II assembly . Bioarchitecture . 3 . 4 . 77–85 . July 2013 . 24002531 . 4201608 . 10.4161/bioa.26133 .
- Heissler SM, Manstein DJ . Nonmuscle myosin-2: mix and match . Cellular and Molecular Life Sciences . 70 . 1 . 1–21 . January 2013 . 22565821 . 3535348 . 10.1007/s00018-012-1002-9 .
- Heissler SM, Sellers JR . Kinetic Adaptations of Myosins for Their Diverse Cellular Functions . Traffic . 17 . 8 . 839–59 . August 2016 . 26929436 . 5067728 . 10.1111/tra.12388 .
- Ma X, Adelstein RS . The role of vertebrate nonmuscle Myosin II in development and human disease . Bioarchitecture . 4 . 3 . 88–102 . 2014 . 25098841 . 4201603 . 10.4161/bioa.29766 .
- Vicente-Manzanares M, Ma X, Adelstein RS, Horwitz AR . Non-muscle myosin II takes centre stage in cell adhesion and migration . Nature Reviews. Molecular Cell Biology . 10 . 11 . 778–90 . November 2009 . 19851336 . 2834236 . 10.1038/nrm2786 .
- D'Apolito M, Guarnieri V, Boncristiano M, Zelante L, Savoia A . Cloning of the murine non-muscle myosin heavy chain IIA gene ortholog of human MYH9 responsible for May-Hegglin, Sebastian, Fechtner, and Epstein syndromes . Gene . 286 . 2 . 215–22 . March 2002 . 11943476 . 10.1016/S0378-1119(02)00455-9 .
- Ma X, Jana SS, Conti MA, Kawamoto S, Claycomb WC, Adelstein RS . Ablation of nonmuscle myosin II-B and II-C reveals a role for nonmuscle myosin II in cardiac myocyte karyokinesis . Molecular Biology of the Cell . 21 . 22 . 3952–62 . November 2010 . 20861308 . 2982113 . 10.1091/mbc.E10-04-0293 .
- Beach JR, Hammer JA . Myosin II isoform co-assembly and differential regulation in mammalian systems . Experimental Cell Research . 334 . 1 . 2–9 . May 2015 . 25655283 . 4433797 . 10.1016/j.yexcr.2015.01.012 .
- Beach JR, Shao L, Remmert K, Li D, Betzig E, Hammer JA . Nonmuscle myosin II isoforms coassemble in living cells . Current Biology . 24 . 10 . 1160–6 . May 2014 . 24814144 . 4108432 . 10.1016/j.cub.2014.03.071 . 2014CBio...24.1160B .
- Shutova MS, Asokan SB, Talwar S, Assoian RK, Bear JE, Svitkina TM . Self-sorting of nonmuscle myosins IIA and IIB polarizes the cytoskeleton and modulates cell motility . The Journal of Cell Biology . 216 . 9 . 2877–2889 . September 2017 . 28701425 . 5584186 . 10.1083/jcb.201705167 .
- Eddinger TJ, Meer DP . Myosin II isoforms in smooth muscle: heterogeneity and function . American Journal of Physiology. Cell Physiology . 293 . 2 . C493–508 . August 2007 . 17475667 . 10.1152/ajpcell.00131.2007 . 9024520 .
- Sellers JR . Myosins: a diverse superfamily . Biochimica et Biophysica Acta (BBA) - Molecular Cell Research . 1496 . 1 . 3–22 . March 2000 . 10722873 . 10.1016/S0167-4889(00)00005-7 . free .
- Conti MA, Even-Ram S, Liu C, Yamada KM, Adelstein RS . Defects in cell adhesion and the visceral endoderm following ablation of nonmuscle myosin heavy chain II-A in mice . The Journal of Biological Chemistry . 279 . 40 . 41263–6 . October 2004 . 15292239 . 10.1074/jbc.C400352200 . free .
- Wang A, Ma X, Conti MA, Liu C, Kawamoto S, Adelstein RS . Nonmuscle myosin II isoform and domain specificity during early mouse development . Proceedings of the National Academy of Sciences of the United States of America . 107 . 33 . 14645–50 . August 2010 . 20679233 . 2930417 . 10.1073/pnas.1004023107 . 2010PNAS..10714645W . free .
- Zhang Y, Conti MA, Malide D, Dong F, Wang A, Shmist YA, Liu C, Zerfas P, Daniels MP, Chan CC, Kozin E, Kachar B, Kelley MJ, Kopp JB, Adelstein RS . Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A . Blood . 119 . 1 . 238–50 . January 2012 . 21908426 . 3251230 . 10.1182/blood-2011-06-358853 .
- Crish J, Conti MA, Sakai T, Adelstein RS, Egelhoff TT . Keratin 5-Cre-driven excision of nonmuscle myosin IIA in early embryo trophectoderm leads to placenta defects and embryonic lethality . Developmental Biology . 382 . 1 . 136–48 . October 2013 . 23911870 . 4186751 . 10.1016/j.ydbio.2013.07.017 .
- Burgess SA, Yu S, Walker ML, Hawkins RJ, Chalovich JM, Knight PJ . Structures of smooth muscle myosin and heavy meromyosin in the folded, shutdown state . Journal of Molecular Biology . 372 . 5 . 1165–78 . October 2007 . 17707861 . 10.1016/j.jmb.2007.07.014 .
- Jung HS, Komatsu S, Ikebe M, Craig R . Head-head and head-tail interaction: a general mechanism for switching off myosin II activity in cells . Molecular Biology of the Cell . 19 . 8 . 3234–42 . August 2008 . 18495867 . 2488288 . 10.1091/mbc.E08-02-0206 .
- Wendt T, Taylor D, Messier T, Trybus KM, Taylor KA . Visualization of head-head interactions in the inhibited state of smooth muscle myosin . The Journal of Cell Biology . 147 . 7 . 1385–90 . December 1999 . 10613897 . 2174251 . 10.1083/jcb.147.7.1385 .
- Milton DL, Schneck AN, Ziech DA, Ba M, Facemyer KC, Halayko AJ, Baker JE, Gerthoffer WT, Cremo CR . Direct evidence for functional smooth muscle myosin II in the 10S self-inhibited monomeric conformation in airway smooth muscle cells . Proceedings of the National Academy of Sciences of the United States of America . 108 . 4 . 1421–6 . January 2011 . 21205888 . 3029703 . 10.1073/pnas.1011784108 . 2011PNAS..108.1421M . free .
- Grum-Schwensen B, Klingelhofer J, Berg CH, El-Naaman C, Grigorian M, Lukanidin E, Ambartsumian N . Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene . Cancer Research . 65 . 9 . 3772–80 . May 2005 . 15867373 . 10.1158/0008-5472.CAN-04-4510 . free .
- Li ZH, Bresnick AR . The S100A4 metastasis factor regulates cellular motility via a direct interaction with myosin-IIA . Cancer Research . 66 . 10 . 5173–80 . May 2006 . 16707441 . 10.1158/0008-5472.CAN-05-3087 .
- Dahan I, Petrov D, Cohen-Kfir E, Ravid S . The tumor suppressor Lgl1 forms discrete complexes with NMII-A and Par6α-aPKCζ that are affected by Lgl1 phosphorylation . Journal of Cell Science . 127 . Pt 2 . 295–304 . January 2014 . jcs.127357 . 24213535 . 10.1242/jcs.127357 . free .
- Ravid S . The tumor suppressor Lgl1 regulates front-rear polarity of migrating cells . Cell Adhesion & Migration . 8 . 4 . 378–83 . 2014 . 25482644 . 4594313 . 10.4161/cam.29387 .
- Hundt N, Steffen W, Pathan-Chhatbar S, Taft MH, Manstein DJ . Load-dependent modulation of non-muscle myosin-2A function by tropomyosin 4.2 . Scientific Reports . 6 . 20554 . February 2016 . 26847712 . 4742800 . 10.1038/srep20554 . 2016NatSR...620554H .
- Lin YH, Zhen YY, Chien KY, Lee IC, Lin WC, Chen MY, Pai LM . LIMCH1 regulates nonmuscle myosin-II activity and suppresses cell migration . Molecular Biology of the Cell . 28 . 8 . 1054–1065 . April 2017 . 28228547 . 5391182 . 10.1091/mbc.E15-04-0218 .
- Kelley MJ, Jawien W, Ortel TL, Korczak JF . Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly . Nature Genetics . 26 . 1 . 106–108 . September 2000 . 10973260 . 10.1038/79069 . 47565254 .
- Seri M, Cusano R, Gangarossa S, Caridi G, Bordo D, Lo Nigro C, Ghiggeri GM, Ravazzolo R, Savino M, Del Vecchio M, d'Apolito M, Iolascon A, Zelante LL, Savoia A, Balduini CL, Noris P, Magrini U, Belletti S, Heath KE, Babcock M, Glucksman MJ, Aliprandis E, Bizzaro N, Desnick RJ, Martignetti JA . Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium . Nature Genetics . 26 . 1 . 103–105 . September 2000 . 10973259 . 10.1038/79063 . 34477122 .
- Seri M, Pecci A, Di Bari F, Cusano R, Savino M, Panza E, Nigro A, Noris P, Gangarossa S, Rocca B, Gresele P, Bizzaro N, Malatesta P, Koivisto PA, Longo I, Musso R, Pecoraro C, Iolascon A, Magrini U, Rodriguez Soriano J, Renieri A, Ghiggeri GM, Ravazzolo R, Balduini CL, Savoia A . MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness . Medicine . 82 . 3 . 203–215 . May 2003 . 12792306 . 10.1097/01.md.0000076006.64510.5c . 25549125 . free .
- Balduini CL, Pecci A, Savoia A . Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias . British Journal of Haematology . 154 . 2 . 161–174 . July 2011 . 21542825 . 10.1111/j.1365-2141.2011.08716.x . free .
- Book: Savoia A, Pecci A . Adam MP, Ardinger HH, et al. . MYH9-Related Disease . GeneReviews® . Seattle (WA) . 1993 . 20301740 . University of Washington, Seattle .
- Noris P, Biino G, Pecci A, Civaschi E, Savoia A, Seri M, Melazzini F, Loffredo G, Russo G, Bozzi V, Notarangelo LD, Gresele P, Heller PG, Pujol-Moix N, Kunishima S, Cattaneo M, Bussel J, De Candia E, Cagioni C, Ramenghi U, Barozzi S, Fabris F, Balduini CL . Platelet diameters in inherited thrombocytopenias: analysis of 376 patients with all known disorders . Blood . 124 . 6 . e4–e10 . August 2014 . 24990887 . 4126341 . 10.1182/blood-2014-03-564328 .
- Pecci A, Klersy C, Gresele P, Lee KJ, De Rocco D, Bozzi V, Russo G, Heller PG, Loffredo G, Ballmaier M, Fabris F, Beggiato E, Kahr WH, Pujol-Moix N, Platokouki H, Van Geet C, Noris P, Yerram P, Hermans C, Gerber B, Economou M, De Groot M, Zieger B, De Candia E, Fraticelli V, Kersseboom R, Piccoli GB, Zimmermann S, Fierro T, Glembotsky AC, Vianello F, Zaninetti C, Nicchia E, Güthner C, Baronci C, Seri M, Knight PJ, Balduini CL, Savoia A . MYH9-related disease: a novel prognostic model to predict the clinical evolution of the disease based on genotype-phenotype correlations . Human Mutation . 35 . 2 . 236–47 . February 2014 . 24186861 . 6233870 . 10.1002/humu.22476 .
- Verver EJ, Topsakal V, Kunst HP, Huygen PL, Heller PG, Pujol-Moix N, Savoia A, Benazzo M, Fierro T, Grolman W, Gresele P, Pecci A . Nonmuscle Myosin Heavy Chain IIA Mutation Predicts Severity and Progression of Sensorineural Hearing Loss in Patients With MYH9-Related Disease . Ear and Hearing . 37 . 1 . 112–120 . January 2016 . 26226608 . 10.1097/AUD.0000000000000198 . 11336/43541 . free .
- Pecci A, Biino G, Fierro T, Bozzi V, Mezzasoma A, Noris P, Ramenghi U, Loffredo G, Fabris F, Momi S, Magrini U, Pirastu M, Savoia A, Balduini C, Gresele P . Alteration of liver enzymes is a feature of the MYH9-related disease syndrome . PLOS ONE . 7 . 4 . e35986 . 2012 . 22558294 . 3338476 . 10.1371/journal.pone.0035986 . free . 2012PLoSO...735986P .
- Kunishima S, Matsushita T, Kojima T, Sako M, Kimura F, Jo EK, Inoue C, Kamiya T, Saito H . Immunofluorescence analysis of neutrophil nonmuscle myosin heavy chain-A in MYH9 disorders: association of subcellular localization with MYH9 mutations . Laboratory Investigation; A Journal of Technical Methods and Pathology . 83 . 1 . 115–122 . January 2003 . 12533692 . 10.1097/01.LAB.0000050960.48774.17 . free .
- Savoia A, De Rocco D, Panza E, Bozzi V, Scandellari R, Loffredo G, Mumford A, Heller PG, Noris P, De Groot MR, Giani M, Freddi P, Scognamiglio F, Riondino S, Pujol-Moix N, Fabris F, Seri M, Balduini CL, Pecci A . Heavy chain myosin 9-related disease (MYH9 -RD): neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder . Thrombosis and Haemostasis . 103 . 4 . 826–832 . April 2010 . 20174760 . 10.1160/TH09-08-0593 . free . 3819344 . 11336/15532 .
- Kitamura K, Yoshida K, Shiraishi Y, Chiba K, Tanaka H, Furukawa K, Miyano S, Ogawa S, Kunishima S . Normal neutrophil myosin IIA localization in an immunofluorescence analysis can rule out MYH9 disorders . Journal of Thrombosis and Haemostasis . 11 . 11 . 2071–2073 . November 2013 . 24106837 . 10.1111/jth.12406 . free .
- Greinacher A, Pecci A, Kunishima S, Althaus K, Nurden P, Balduini CL, Bakchoul T . Diagnosis of inherited platelet disorders on a blood smear: a tool to facilitate worldwide diagnosis of platelet disorders . Journal of Thrombosis and Haemostasis . 15 . 7 . 1511–1521 . July 2017 . 28457011 . 10.1111/jth.13729 .
- Saposnik B, Binard S, Fenneteau O, Nurden A, Nurden P, Hurtaud-Roux MF, Schlegel N . Mutation spectrum and genotype-phenotype correlations in a large French cohort of MYH9-Related Disorders . Molecular Genetics & Genomic Medicine . 2 . 4 . 297–312 . July 2014 . 25077172 . 4113270 . 10.1002/mgg3.68 .
- Kunishima S, Matsushita T, Yoshihara T, Nakase Y, Yokoi K, Hamaguchi M, Saito H . First description of somatic mosaicism in MYH9 disorders . British Journal of Haematology . 128 . 3 . 360–365 . February 2005 . 15667538 . 10.1111/j.1365-2141.2004.05323.x .
- Kunishima S, Takaki K, Ito Y, Saito H . Germinal mosaicism in MYH9 disorders: a family with two affected siblings of normal parents . British Journal of Haematology . 145 . 2 . 260–262 . April 2009 . 19208103 . 10.1111/j.1365-2141.2009.07584.x .
- Kunishima S, Kitamura K, Matsumoto T, Sekine T, Saito H . Somatic mosaicism in MYH9 disorders: the need to carefully evaluate apparently healthy parents . British Journal of Haematology . 165 . 6 . 885–887 . June 2014 . 24611568 . 10.1111/bjh.12797 .
- Pecci A, Panza E, Pujol-Moix N, Klersy C, Di Bari F, Bozzi V, Gresele P, Lethagen S, Fabris F, Dufour C, Granata A, Doubek M, Pecoraro C, Koivisto PA, Heller PG, Iolascon A, Alvisi P, Schwabe D, De Candia E, Rocca B, Russo U, Ramenghi U, Noris P, Seri M, Balduini CL, Savoia A . Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease . Human Mutation . 29 . 3 . 409–417 . March 2008 . 18059020 . 10.1002/humu.20661 . 11336/105263 . free .
- Kunishima S, Yoshinari M, Nishio H, Ida K, Miura T, Matsushita T, Hamaguchi M, Saito H . Haematological characteristics of MYH9 disorders due to MYH9 R702 mutations . European Journal of Haematology . 78 . 3 . 220–226 . March 2007 . 17241369 . 10.1111/j.1600-0609.2006.00806.x .
- Pecci A, Gresele P, Klersy C, Savoia A, Noris P, Fierro T, Bozzi V, Mezzasoma AM, Melazzini F, Balduini CL . Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations . Blood . 116 . 26 . 5832–5837 . December 2010 . 20844233 . 10.1182/blood-2010-08-304725 .
- Pecci A, Granata A, Fiore CE, Balduini CL . Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome) . Nephrology, Dialysis, Transplantation . 23 . 8 . 2690–2692 . August 2008 . 18503011 . 10.1093/ndt/gfn277 .
- Sekine T, Konno M, Sasaki S, Moritani S, Miura T, Wong WS, Nishio H, Nishiguchi T, Ohuchi MY, Tsuchiya S, Matsuyama T, Kanegane H, Ida K, Miura K, Harita Y, Hattori M, Horita S, Igarashi T, Saito H, Kunishima S . Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease . Kidney International . 78 . 2 . 207–214 . July 2010 . 20200500 . 10.1038/ki.2010.21 .
- Pecci A, Verver EJ, Schlegel N, Canzi P, Boccio CM, Platokouki H, Krause E, Benazzo M, Topsakal V, Greinacher A . Cochlear implantation is safe and effective in patients with MYH9-related disease . Orphanet Journal of Rare Diseases . 9 . 100 . June 2014 . 24980457 . 4105151 . 10.1186/1750-1172-9-100 . free .
- Schramek D, Sendoel A, Segal JP, Beronja S, Heller E, Oristian D, Reva B, Fuchs E . Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas . Science . 343 . 6168 . 309–13 . January 2014 . 24436421 . 4159249 . 10.1126/science.1248627 . 2014Sci...343..309S .
- Conti MA, Saleh AD, Brinster LR, Cheng H, Chen Z, Cornelius S, Liu C, Ma X, Van Waes C, Adelstein RS . Conditional deletion of nonmuscle myosin II-A in mouse tongue epithelium results in squamous cell carcinoma . Scientific Reports . 5 . 14068 . September 2015 . 26369831 . 4572924 . 10.1038/srep14068 . 2015NatSR...514068A .
- Kas SM, de Ruiter JR, Schipper K, Annunziato S, Schut E, Klarenbeek S, Drenth AP, van der Burg E, Klijn C, Ten Hoeve JJ, Adams DJ, Koudijs MJ, Wesseling J, Nethe M, Wessels LF, Jonkers J . Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma . Nature Genetics . 49 . 8 . 1219–1230 . August 2017 . 28650484 . 10.1038/ng.3905 . 3255229 .
- Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, Mokrzycki MH, Schelling JR, Simon E, Trachtman H, Vlahov D, Winkler CA . MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis . Nature Genetics . 40 . 10 . 1175–84 . October 2008 . 18794856 . 2827354 . 10.1038/ng.226 .
- Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J, Patterson N, Tandon A, Powe NR, Fink NE, Sadler JH, Weir MR, Abboud HE, Adler SG, Divers J, Iyengar SK, Freedman BI, Kimmel PL, Knowler WC, Kohn OF, Kramp K, Leehey DJ, Nicholas SB, Pahl MV, Schelling JR, Sedor JR, Thornley-Brown D, Winkler CA, Smith MW, Parekh RS . MYH9 is associated with nondiabetic end-stage renal disease in African Americans . Nature Genetics . 40 . 10 . 1185–92 . October 2008 . 18794854 . 2614692 . 10.1038/ng.232 .
- Behar DM, Rosset S, Tzur S, Selig S, Yudkovsky G, Bercovici S, Kopp JB, Winkler CA, Nelson GW, Wasser WG, Skorecki K . African ancestry allelic variation at the MYH9 gene contributes to increased susceptibility to non-diabetic end-stage kidney disease in Hispanic Americans . Human Molecular Genetics . 19 . 9 . 1816–27 . May 2010 . 20144966 . 2850615 . 10.1093/hmg/ddq040 .
- Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ, Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR . Association of trypanolytic ApoL1 variants with kidney disease in African Americans . Science . 329 . 5993 . 841–5 . August 2010 . 20647424 . 2980843 . 10.1126/science.1193032 . 2010Sci...329..841G .
- Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekegn A, Bekele E, Bradman N, Wasser WG, Behar DM, Skorecki K . Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene . Human Genetics . 128 . 3 . 345–50 . September 2010 . 20635188 . 2921485 . 10.1007/s00439-010-0861-0 .
- Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, Mokrzycki MH, Kimmel PL, Limou S, Ahuja TS, Berns JS, Fryc J, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Vlahov D, Pollak M, Winkler CA . APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy . Journal of the American Society of Nephrology . 22 . 11 . 2129–37 . November 2011 . 21997394 . 3231787 . 10.1681/ASN.2011040388 .
- Cooke JN, Bostrom MA, Hicks PJ, Ng MC, Hellwege JN, Comeau ME, Divers J, Langefeld CD, Freedman BI, Bowden DW . Polymorphisms in MYH9 are associated with diabetic nephropathy in European Americans . Nephrology, Dialysis, Transplantation . 27 . 4 . 1505–11 . April 2012 . 21968013 . 3315672 . 10.1093/ndt/gfr522 .
- Cheng W, Zhou X, Zhu L, Shi S, Lv J, Liu L, Zhang H . Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with the progression of IgA nephropathy in Chinese . Nephrology, Dialysis, Transplantation . 26 . 8 . 2544–9 . August 2011 . 21245129 . 10.1093/ndt/gfq768 . free .
- O'Seaghdha CM, Parekh RS, Hwang SJ, Li M, Köttgen A, Coresh J, Yang Q, Fox CS, Kao WH . The MYH9/APOL1 region and chronic kidney disease in European-Americans . Human Molecular Genetics . 20 . 12 . 2450–6 . June 2011 . 21429915 . 3098737 . 10.1093/hmg/ddr118 .
- Chen Pei-jer . Wu CC, Lin YH, Lu YC, Chen PJ, Yang WS, Hsu CJ, Chen PL . Application of massively parallel sequencing to genetic diagnosis in multiplex families with idiopathic sensorineural hearing impairment . PLOS ONE . 8 . 2 . e57369 . 2013 . 23451214 . 3579845 . 10.1371/journal.pone.0057369 . 2013PLoSO...857369W . free .
- Kim SJ, Lee S, Park HJ, Kang TH, Sagong B, Baek JI, Oh SK, Choi JY, Lee KY, Kim UK . Genetic association of MYH genes with hereditary hearing loss in Korea . Gene . 591 . 1 . 177–82 . October 2016 . 27393652 . 10.1016/j.gene.2016.07.011 .
- Miyagawa M, Naito T, Nishio SY, Kamatani N, Usami S . Targeted exon sequencing successfully discovers rare causative genes and clarifies the molecular epidemiology of Japanese deafness patients . PLOS ONE . 8 . 8 . e71381 . 2013 . 23967202 . 3742761 . 10.1371/journal.pone.0071381 . 2013PLoSO...871381M . free .
- England K, Ashford D, Kidd D, Rumsby M . PKC epsilon is associated with myosin IIA and actin in fibroblasts . Cellular Signalling . 14 . 6 . 529–36 . June 2002 . 11897493 . 10.1016/S0898-6568(01)00277-7 .